The microvacular thrombi of colonic tissue in ulcerative colitis

Digestive Diseases and Sciences

Volumn 52, Issue 9, 2007, Pages 2236-2240

  He, Guobin ^a   Ouyang, Qin ^b   Chen, Daiyun ^b   Li, Fengyuan ^b   Zhou, Jingguo ^a  

^a AFFILIATED HOSPITAL OF NORTH SICHUAN MEDICAL COLLEGE   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Microvacular thrombi; Thrombosis; Ulcerative colitis

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD61; UNCLASSIFIED DRUG; AZO COMPOUND; BETA3 INTEGRIN; DIAGNOSTIC AGENT; MARTIUS SCARLET BLUE TRICHROME;

ADULT; AGE DISTRIBUTION; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL ARTICLE; COLON; COLON BIOPSY; COLON CARCINOMA; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LOGISTIC REGRESSION ANALYSIS; MALE; MICROTHROMBUS; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; SAMPLE; SCORING SYSTEM; SEX RATIO; STATISTICAL SIGNIFICANCE; ULCERATIVE COLITIS; BIOPSY; FOLLOW UP; IMMUNOLOGY; METABOLISM; MICROCIRCULATION; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REGRESSION ANALYSIS; THROMBOSIS; VASCULARIZATION;

ADULT; AZO COMPOUNDS; BIOPSY; COLITIS, ULCERATIVE; COLON; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTEGRIN BETA3; MALE; MICROCIRCULATION; MIDDLE AGED; PROGNOSIS; REGRESSION ANALYSIS; RISK FACTORS; THROMBOSIS;

EID: 34547839707     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-9158-5     Document Type: Article

References (32)

1. Dhillon AP, Anthony A, Sim R, Wakefield AJ, Sankey EA, Hudson M, Allison MC, Pounder RE (1992) Mucosal capillary thrombi in rectal biopsies. Histopathology 21:127-133
2. Gaffney PR, O'Leary JJ, Doyle CT, Gaffney A, Hogan J, Smew F, Annis P (1991) Response to heparin in patients with ulcerative colitis. Lancet 26(337):238-239
3. Gaffney PR, Doyle CT, Gaffney A, Hogan J, Hayes DP, Annis P (1995) Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastroenterol 90:220-223
4. Evans RC, Wong VS, Morris AI, Rhodes JM (1997) Treatment of corticosteroid-resistant ulcerative colitis with heparin: A report of 16 cases. Aliment Pharmacol Ther 11:1037-1040
5. Folwaczny C, Wiebecke B, Loeschke K (1999) Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. Am J Gastroenterol 94:1551-1555
6. Torkvist L, Thorlacius H, Sjoqvist U, Bohman L, Lapidus A, Flood L, Agren B, Raud J, Lofberg R (1999) Low molecular weight heparin as adjuvant therapy in active ulcerative colitis. Aliment Pharmacol Ther 13:1323-1328
7. Ang YS, Mahmud N, White B, Byrne M, Kelly A, Lawler M, McDonald GS, Smith OP, Keeling PW (2000) Randomized comparison of unfractionated heparin with corticosteroids in severe active inflammatory bowel disease. Aliment Pharmacol Ther 14:1015-1022
8. Panes J, Esteve M, Cabre E, Hinojosa J, Andreu M, Sans M, Fernandez-Banares F, Feu F, Gassull MA, Pique JM (2000) Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. Gastroenterology 119:903-908
9. Papa A, Danese S, Gasbarrini A, Gasbarrini G (2000) Review article: Potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease. Aliment Pharmacol Ther 14:1403-1409
10. Dotan I, Hallak A, Arber N, Santo M, Alexandrowitz A, Knaani Y, Hershkoviz R, Brazowski E, Halpern Z (2001) Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: An open trial. Dig Dis Sci 46:2239-2244
11. Thompson NP, Wakefield AJ, Pounder RE (1995) Inherited disorders of coagulation appear to protect against inflammatory bowel disease. Gastroenterology 108:1011-1015
12. Spina L, Saibeni S, Battaglioli T, Peyvandi F, de Franchis R, Vecchi M (2005) Thrombosis in inflammatory bowel diseases: Role of inherited thrombophilia. Am J Gastroenterol 100:2036-2041
13. Vecchi M, Sacchi E, Saibeni S, Meucci G, Tagliabue L, Duca F, De Franchis R (2000) Inflammatory bowel diseases are not associated with major hereditary conditions predisposing to thrombosis. Dig Dis Sci 45:1465-1469
14. Salasa M, Sansa A, Sorianoa JC, Reverterb DC, Andersonc JM, Piqua J, Pansa J (2000) Heparin attenuates TNF- induced inflammatory response through a CD11b dependent mechanism. Gut 47:88-96
15. Hogasen AK, Abrahamsen TG (1995) Heparin suppresses lipopolysaccharide- induced monocyte production of several cytokines, but simultaneously stimulates C3 production. Thromb Res 80:179-184
16. Baram D, Rashkovsky M, Hershkoviz R, Drucker I, Reshef T, Ben-Shitrit S, Mekori YA (1997) Inhibitory effects of low molecular weight heparin on mediator release by mast cells: preferential inhibition of cytokine production and mast cell-dependent cutaneous inflammation. Clin Exp Immunol 110:485-491
17. Vrij AA, Jansen JM, Schoon EJ, de Bruine A, Hemker HC, Stockbrugger RW (2001) Low molecular weight heparin treatment in steroid refractory ulcerative colitis: Clinical outcome and influence on mucosal capillary thrombi. Scand J Gastroenterol Suppl 234:41-47
18. Malhotra S, Kondal A, Shafiq N, Sidhu S, Bhasin DK, Pandhi P (2004) A comparison of observational studies and controlled trials of heparin in ulcerative colitis. Int J Clin Pharmacol Ther 42:690-694
19. Hudson M, Chitolie A, Hutton RA, Smith MS, Pounder RE, Wakefield AJ (1996) Thrombotic vascular risk factors in inflammatory bowel disease. Gut 38:733-737
20. Bernstein CN, Blanchard JF, Houston DS, Wajda A (2001) The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: A population-based cohort study. Thromb Haemost 85:430-434
21. Miehsler W, Reinisch W, Valic E, Osterode W, Tillinger W, Feichtenschlager T, Grisar J, Machold K, Scholz S, Vogelsang H, Novacek G (2004) Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 53:542-548
22. Sonoda K, Ikeda S, Mizuta Y, Miyahara Y, Kohno S (2004) Evaluation of venous thromboembolism and coagulation-fibrinolysis markers in Japanese patients with inflammatory bowel disease. J Gastroenterol 39:948-954
23. Larsen TB, Nielsen JN, Fredholm L, Lund ED, Brandslund I, Munkholm P, Hey H (2002) Platelets and anticoagulant capacity in patients with inflammatory bowel disease. Pathophysiol Haemost Thromb 32:92-96
24. Biancone L, Scopinaro F, Maletta M, Monteleone G, Luzza F, Banci M, Mercantini P, Renda T, Pallone F (1994) Circulating D dimer in inflammatory bowel disease. It J Gastroenterol 26:116-120
25. Hayat M, Ariens RA, Moayyedi P, Grant PJ, O'Mahony S (2002) Coagulation factor XIII and markers of thrombin generation and fibrinolysis in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 14:249-256
26. Souto JC, Martinez E, Roca M, Mateo J, Pujol J, Gonzalez D, Fontcuberta J (1995) Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci 40:1883-1889
27. Vrij AA, Rijken J, van Wersch JW, Stockbrugger RW (2003) Coagulation and fibrinolysis in inflammatory bowel disease and in giant cell arteritis. Pathophysiol Haemost Thromb 33:75-83
28. Van Bodegraven AA, Tuynman HA, Schoorl M, Kruishoop AM, Bartels PC (1995) Fibrinolytic split products, fibrinolysis, and factor XIII activity in inflammatory bowel disease. Scand J Gastroenterol 30:580-585
29. van Wersch JW, Houben P, Rijken J (1990) Platelet count, platelet function, coagulation activity and fibrinolysis in the acute phase of inflammatory bowel disease. J Clin Chem Clin Biochem 28:513-517
30. Dotan I, Hershkoviz R, Karmeli F, Brazowski E, Peled Y, Rachmilewitz D, Halpern Z (2001) Heparin and low-molecular-weight heparin (enoxaparin) significantly ameliorate experimental colitis in rats. Aliment Pharmacol Ther 15:1687-1697
31. Bloom S, Kiilerich S, Lassen MR, Forbes A, Leiper K, Langholz E, Irvine EJ, O'Morain C, Lowson D, Orm S (2004) Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis. Aliment Pharmacol Ther 15:871-878
32. Day R, Ilyas M, Daszak P, Talbot I, Forbes A (1999) Expression of syndecan-1 in inflammatory bowel disease and a possible mechanism of heparin therapy. Dig Dis Sci 44:2508-2515